# Image Recommendations (Medicinal Chemistry Emphasis)
## PHA 548 • Sedative–Hypnotics Repository

This document lists recommended figures to supplement lectures, assessments, and the study guide.
Goal: make structure → interactions → metabolism → therapeutic decisions visually obvious.

---

## Global Figures (Use in README + Study Guide + all lectures)

### G1. “Three Levers of Sleep” Systems Diagram
**Purpose:** Prevent GABA-centric misconception.
- Lever 1: Increase inhibition (GABA_A PAMs)
- Lever 2: Reduce wake drive (Orexin antagonists)
- Lever 3: Reset timing (Melatonin agonists)

**Recommended format:** 1 slide, icon-based pathway diagram.

---

### G2. Target Location Map (CNS Sleep Targets)
**Purpose:** Connect target biology to clinical outcomes.
- GABA_A: widespread cortical inhibition
- Orexin (hypothalamus): wake drive
- MT1/MT2 (SCN): circadian timing

**Recommended format:** simple brain-region schematic (SCN, hypothalamus).

---

### G3. PK Drivers for CNS Drugs (Concept Figure)
**Purpose:** Teach “PK dominates” for CNS agents.
Include: logP/pKa/PSA → BBB penetration → onset/duration/next-day impairment.

**Recommended format:** causal flow diagram.

---

## Lecture 01 (Benzodiazepines) — Figure Set

### L1-1. GABA_A receptor pentamer with binding sites labeled
- Orthosteric GABA sites (β–α interfaces)
- Benzodiazepine site (α–γ interface)
- Barbiturate/propofol/etomidate regions (distinct allosteric sites)

**Add color key:** α1/α2/α3/α5 functional effects.

---

### L1-2. BZD pharmacophore overlay (Diazepam template)
Label required features:
- Ring A aromatic + C7 EWG
- C2 carbonyl
- Ring C phenyl and substitution map (2′ vs 4′)

---

### L1-3. “SAR hotspot” figure (C7, C3, Ring C)
**Purpose:** make SAR testable visually.

---

### L1-4. Metabolism pathway panels (3 panels)
- Long-acting: diazepam/flurazepam (active metabolites)
- 3-OH group: temazepam/lorazepam/oxazepam (UGT glucuronidation)
- Soft drug: remimazolam (ester hydrolysis)

---

### L1-5. “Next-day impairment risk” visual
Bar chart style:
Active metabolites + long t½ → higher residual sedation/falls.

---

## Lecture 02 (Z-drugs) — Figure Set

### L2-1. Shared BZD-site pharmacophore map (scaffold-agnostic)
**Purpose:** show why Z-drugs bind without a diazepine ring.
- Aromatic π-system
- H-bond acceptor
- Lipophilic tail pocket

---

### L2-2. Three-structure comparison panel
Zolpidem vs zaleplon vs eszopiclone with callouts:
- metabolic “soft spots”
- polarity differences
- duration intent (onset vs maintenance)

---

### L2-3. Metabolic clearance map
- Zolpidem: CYP3A4 oxidation → inactive metabolites
- Zaleplon: aldehyde oxidase route → very short
- Eszopiclone: CYP metabolism → longer duration; dysgeusia association callout

---

### L2-4. “Complex sleep behaviors” warning figure
**Purpose:** address misconceptions and safety counseling.

---

## Lecture 03 (Melatonin/Orexin/Barbiturates) — Figure Set

### L3-1. MT1 vs MT2 signaling diagram
Tie to:
- sleep propensity (MT1 emphasis)
- circadian phase shifting (MT2 emphasis)
Include SCN context.

---

### L3-2. Orexin pathway diagram (wake drive)
Label OX1/OX2 receptors and arousal circuits.

---

### L3-3. DORA design logic: half-life tuning
Show:
lipophilicity + clearance tuning → duration control → next-day sedation risk.

---

### L3-4. Barbiturate SAR base figure
Barbituric acid core with C5 substituent variation:
- increased lipophilicity → faster onset / redistribution
- high risk: narrow therapeutic index, direct gating at high dose

---

## File Naming & Placement Recommendations (Consistency)

Place figures inside each lecture folder:
- lectures/Lecture_01_BZD_Sedative_Hypnotics/figures/
- lectures/Lecture_02_NonBZD_Sedative_Hypnotics/figures/
- lectures/Lecture_03_Alternative_Hypnotic_Pathways/figures/

Use consistent naming:
- L01_GABAA_Sites.png
- L01_BZD_Pharmacophore.png
- L01_Metabolism_Panels.png
- L02_BZDsite_Pharmacophore_Zdrugs.png
- L03_Orexin_Pathway.png
- L03_MT1_MT2_SCN.png
